Comparative efficacy and safety of antidiabetic drug regimens added to metformin monotherapy in patients with type 2 diabetes: A network meta-analysis

PLoS ONE

Volumn 10, Issue 4, 2015, Pages

  Mearns, Elizabeth S ^a,b   Sobieraj, Diana M ^a,b   White, C Michael ^a,b   Saulsberry, Whitney J ^a,b   Kohn, Christine G ^c   Doleh, Yunes ^a   Zaccaro, Eric ^a   Coleman, Craig I ^a,b  

^a UNIVERSITY OF CONNECTICUT   (United States)

^b HARTFORD HOSPITAL   (United States)

^c UNIVERSITY OF SAINT JOSEPH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; ALOGLIPTIN; ALOGLIPTIN PLUS PIOGLITAZONE; ANTIDIABETIC AGENT; CANAGLIFLOZIN; COLESEVELAM; DAPAGLIFLOZIN; EMPAGLIFLOZIN; EMPAGLIFLOZIN PLUS LINAGLIPTIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; INSULIN GLARGINE; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; MIGLITOL; NATEGLINIDE; PIOGLITAZONE; PLACEBO; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; UNCLASSIFIED DRUG; UNINDEXED DRUG; VILDAGLIPTIN; GLYCOSYLATED HEMOGLOBIN;

ADJUVANT THERAPY; ARTICLE; BODY WEIGHT; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT INFECTION; GLYCEMIC CONTROL; HUMAN; HYPOGLYCEMIA; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION; BLOOD PRESSURE; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; PATHOPHYSIOLOGY; SYSTOLE; TREATMENT OUTCOME;

SUS;

BLOOD PRESSURE; BODY WEIGHT; DIABETES MELLITUS, TYPE 2; DRUG THERAPY, COMBINATION; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; METFORMIN; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SYSTOLE; TREATMENT OUTCOME;

EID: 84928628823     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0125879     Document Type: Article

References (78)

1. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012; 35(6):1364-79. doi: 10.2337/dc12-0413 PMID: 22517736
2. Higgins JPT, Green S (editors). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [updated March 2011]. The Cochrane Collaboration, 2011. Available from www.cochranehandbook.org. (Last accessed on June 27, 2014).
3. Hoaglin DC, Hawkins N, Jansen JP, Scott DA, Itzler R, Cappelleri JC et al. Conducting indirect-treatment-comparison and network-meta-analysis studies: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 2. Value Health. 2011; 14(4):429-37. doi: 10.1016/j.jval.2011.01.011 PMID: 21669367
4. Phung OJ, Scholle JM, Talwar M, Coleman CI. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. JAMA. 2010; 303 (14):1410-18. doi: 10.1001/jama.2010.405 PMID: 20388897
5. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. (2011) The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011; 343:d5928. doi: 10.1136/bmj.d5928 PMID: 22008217
6. Package 'netmeta'. June 24, 2014. Available at: http://cran.r-project.org/web/packages/netmeta/netmeta.pdf (Last accessed on June 27, 2014).
7. US Food and Drug Administration. Guidelines for industry: diabetes mellitus: developing drugs and therapeutic biologics for treatment and prevention. Available at: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm071624.pdf (Last accessed on October 3, 2014).
8. St Jeor ST, Brunner RL, Harrington ME, Scott BJ, Daugherty SA, Cutter GR, et al. A classification system to evaluate weight maintainers, gainers, and losers. J Am Diet Assoc. 1997; 97(5):481-8. PMID: 9145085
9. Reboldi G, Gentile G, Angeli F, Ambrosio G, Mancia G, Verdecchia P. Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens. 2011; 29(7):1253-69. doi: 10.1097/HJH.0b013e3283469976 PMID: 21505352
10. Defronzo RA, Lewin A, Patel S, Liu D, Kaste R, Woerle HJ, et al. Fixed dose combinations of empagliflozin/linagliptin for 24 weeks as add-on to metformin in subjects with type 2 diabetes (T2D). Poster presentation, American Diabetes Association (ADA) 74th Scientific Sessions. 13-17 June 2014, San Francisco, CA.
11. Bolli GB, Munteanu M, Dotsenko S, Niemoeller E, Boka G, Wu Y, et al. Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (Get-Goal-F1). Diabet Med. 2014; 31(2):176-84. doi: 10.1111/dme.12328 PMID: 24117597
12. Derosa G, Bonaventura A, Bianchi L, Romano D, Fogari E, D'Angelo A, et al. Vildagliptin compared to glimepiride on post-prandial lipemia and on insulin resistance in type 2 diabetic patients. Metabolism. 2014; 63(7):957-67. doi: 10.1016/j.metabol.2014.04.008 PMID: 24874591
13. Häring HU, Merker L, Seewaldt-Becker E, Weimer M, Meinicke T, Broedl UC, et al. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebocontrolled trial. Diabetes Care. 2014; 37(6):1650-9. doi: 10.2337/dc13-2105 PMID: 24722494
14. Nauck M, Weinstock RS, Umpierrez GE, Guerci B, Skrivanek Z, Milicevic Z. Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5). Diabetes Care. 2014; 37:2149-58. doi: 10.2337/dc13-2761 PMID: 24742660
15. Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC, et al. Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. Lancet Diabetes Endocrinol. 2014; 2(9):691-700. doi: 10.1016/S2213-8587(14)70120-2 PMID: 24948511
16. White JL, Buchanan P, Li J, Frederich R. A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy. BMC Endocr Disord. 2014; 14(1):17.
17. Charbonnel B, Steinberg H, Eymard E, Xu L, Thakkar P, Prabhu V, et al. Efficacy and safety over 26 weeks of an oral treatment strategy including sitagliptin compared with an injectable treatment strategy with liraglutide in patients with type 2 diabetes mellitus inadequately controlled on metformin: a randomised clinical trial. Diabetologia. 2013; 56(7):1503-11. doi: 10.1007/s00125-013-2905-1 PMID: 23604551
18. Chawla S, Kaushik N, Singh NP, Ghosh RK, Saxena A. Effect of addition of either sitagliptin or pioglitazone in patients with uncontrolled type 2 diabetes mellitus on metformin: A randomized controlled trial. J Pharmacol Pharmacother. 2013; 4(1):27-32. doi: 10.4103/0976-500X.107656 PMID: 23662021
19. Cefalu WT, Leiter LA, Yoon KH, Arias P, Niskanen L, Xie J, et al. Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATASU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. Lancet. 2013; 382 (9896):941-50. doi: 10.1016/S0140-6736(13)60683-2 PMID: 23850055
20. Derosa G, Ragonesi PD, Carbone A, Fogari E, D'Angelo A, Cicero AF, et al. Evaluation of the positive effects on insulin-resistance and β-cell measurements of vildagliptin in addition to metformin in type 2 diabetic patients. Pharmacol Res. 2013; 73:20-6. doi: 10.1016/j.phrs.2013.04.005 PMID: 23624419
21. Lavalle-González FJ, Januszewicz A, Davidson J, Tong C, Qiu R, CanovatchelW, et al. Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial. Diabetologia. 2013; 56(12):2582-92. doi: 10.1007/s00125-013-3039-1 PMID: 24026211
22. Rosenstock J, Seman LJ, Jelaska A, Hantel S, Pinnetti S, Hach T, et al. Efficacy and safety of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, as add-on to metformin in type 2 diabetes with mild hyperglycaemia. Diabetes Obes Metab. 2013; 15(12):1154-60. doi: 10.1111/dom.12185 PMID: 23906374
23. Rosenstock J, Raccah D, Korányi L, Maffei L, Boka G, Miossec P, et al. Efficacy and safety of lixisenatide once daily versus exenatide twice daily in type 2 diabetes inadequately controlled on metformin: a 24-week, randomized, open-label, active-controlled study (GetGoal-X). Diabetes Care. 2013; 36 (10):2945-51. doi: 10.2337/dc12-2709 PMID: 23698396
24. Aschner P, Chan J, Owens DR, Picard S, Wang E, Dain MP, et al. Insulin glargine versus sitagliptin in insulin-naive patients with type 2 diabetes mellitus uncontrolled on metformin (EASIE): a multicentre, randomised open-label trial. Lancet. 2012; 379(9833):2262-9. doi: 10.1016/S0140-6736(12)60439-5 PMID: 22683131
25. Bergenstal RM, Forti A, Chiasson JL, Woloschak M, Boldrin M, Balena R. Efficacy and safety of taspoglutide versus sitagliptin for type 2 diabetes mellitus (T-emerge 4 trial). Diabetes Ther. 2012; 3(1):13. doi: 10.1007/s13300-012-0013-8 PMID: 23138449
26. DeFronzo RA, Burant CF, Fleck P, Wilson C, Mekki Q, Pratley RE. Efficacy and tolerability of the DPP-4 inhibitor alogliptin combined with pioglitazone, in metformin-treated patients with type 2 diabetes. J Clin Endocrinol Metab. 2012; 97(5):1615-22. doi: 10.1210/jc.2011-2243 PMID: 22419732
27. Derosa G, Franzetti IG, Querci F, Carbone A, Ciccarelli L, Piccinni MN, et al. Exenatide plus metformin compared with metformin alone on β-cell function in patients with Type 2 diabetes. Diabet Med. 2012; 29(12):1515-23. doi: 10.1111/j.1464-5491.2012.03699.x PMID: 22540883
28. Derosa G, Carbone A, Franzetti I, Querci F, Fogari E, Bianchi L, et al. Effects of a combination of sitagliptin plus metformin vs metformin monotherapy on glycemic control, β-cell function and insulin resistance in type 2 diabetic patients. Diabetes Res Clin Pract. 2012; 98(1):51-60. doi: 10.1016/j.diabres.2012.05.022 PMID: 22682949
29. Gallwitz B, Guzman J, Dotta F, Guerci B, Simó R, Basson BR, et al. Exenatide twice daily versus glimepiride for prevention of glycaemic deterioration in patients with type 2 diabetes with metformin failure (EUREXA): an open-label, randomised controlled trial. Lancet. 2012; 379(9833):2270-8. doi: 10.1016/S0140-6736(12)60479-6 PMID: 22683137
30. Gallwitz B, Rosenstock J, Rauch T, Bhattacharya S, Patel S, von Eynatten M, et al. 2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial. Lancet. 2012; 380(9840):475-83. doi: 10.1016/S0140-6736(12)60691-6 PMID: 22748821
31. Ljunggren Ö, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjöström CD, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012; 14(11):990-9. doi: 10.1111/j.1463-1326.2012.01630.x PMID: 22651373
32. Pan C, Xing X, Han P, Zheng S, Ma J, Liu J, et al. Efficacy and tolerability of vildagliptin as add-on therapy to metformin in Chinese patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2012; 14 (8):737-44. doi: 10.1111/j.1463-1326.2012.01593.x PMID: 22369287
33. Rizzo MR, Barbieri M, Marfella R, Paolisso G. Reduction of oxidative stress and inflammation by blunting daily acute glucose fluctuations in patients with type 2 diabetes: role of dipeptidyl peptidase-IV inhibition. Diabetes Care. 2012; 35(10):2076-82. PMID: 22688551
34. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012; 35(6):1232-8. doi: 10.2337/dc11-1926 PMID: 22492586
35. Ross SA, Rafeiro E, Meinicke T, Toorawa R, Weber-Born S, Woerle HJ. Efficacy and safety of linagliptin 2.5 mg twice daily versus 5mg once daily in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, placebo-controlled trial. Curr Med Res Opin. 2012; 28(9):1465-74. PMID: 22816729
36. Arechavaleta R, Seck T, Chen Y, Krobot KJ, O'Neill EA, Duran L, et al. Efficacy and safety of treatment with sitagliptin or glimepiride in patients with type 2 diabetes inadequately controlled on metformin monotherapy: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2011; 13(2):160-8. doi: 10.1111/j.1463-1326.2010.01334.x PMID: 21199268
37. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011; 34(9):2015-22. doi: 10.2337/dc11-0606 PMID: 21816980
38. Pfützner A, Schöndorf T, Tschöpe D, Lobmann R, Merke J, Müller J, et al. PIOfix-study: effects of pioglitazone/ metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia. Diabetes Technol Ther. 2011; 13(6):637-43. doi: 10.1089/dia.2010.0233 PMID: 21457065
39. Taskinen MR, Rosenstock J, Tamminen I, Kubiak R, Patel S, Dugi KA, et al. Safety and efficacy of linagliptin as add-on therapy to metformin in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011; 13(1):65-74. doi: 10.1111/j.1463-1326.2010.01326.x PMID: 21114605
40. Wang JS, Lin SD, Lee WJ, Su SL, Lee IT, Tu ST, et al. Effects of acarbose versus glibenclamide on glycemic excursion and oxidative stress in type 2 diabetic patients inadequately controlled by metformin: a 24-week, randomized, open-label, parallel-group comparison. Clin Ther. 2011; 33(12):1932-42. doi: 10.1016/j.clinthera.2011.10.014 PMID: 22078152
41. Yang W, Pan CY, Tou C, Zhao J, Gause-Nilsson I. Efficacy and safety of saxagliptin added to metformin in Asian people with type 2 diabetes mellitus: a randomized controlled trial. Diabetes Res Clin Pract. 2011; 94(2):217-24. doi: 10.1016/j.diabres.2011.07.035 PMID: 21871686
42. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010; 375(9733):2223-33. doi: 10.1016/S0140-6736(10)60407-2 PMID: 20609968
43. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med. 2010; 27(3):318-26. doi: 10.1111/j.1464-5491.2010.02938.x PMID: 20536495
44. Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I, D1680C00001 Investigators. Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract. 2010; 64(12):1619-31. doi: 10.1111/j.1742-1241.2010.02510.x PMID: 20846286
45. Pratley RE, Nauck M, Bailey T, Montanya E, Cuddihy R, Filetti S, et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet. 2010; 375(9724):1447-56. doi: 10.1016/S0140-6736(10)60307-8 PMID: 20417856
46. Rigby SP, Handelsman Y, Lai YL, Abby SL, Tao B, Jones MR. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. Endocr Pract. 2010; 16(1):53-63. doi: 10.4158/EP09146.OR PMID: 19789153
47. Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev. 2010; 26(7):540-9. doi: 10.1002/dmrr.1114 PMID: 20824678
48. DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, et al. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care. 2009; 32(9):1649-55. doi: 10.2337/dc08-1984 PMID: 19478198
49. Ferrannini E, Fonseca V, Zinman B, Matthews D, Ahrén B, Byiers S, et al. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin monotherapy. Diabetes Obes Metab. 2009; 11(2):157-66. doi: 10.1111/j.1463-1326.2008.00994.x PMID: 19125777
50. Goodman M, Thurston H, Penman J. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Horm Metab Res. 2009; 41(5):368-73. doi: 10.1055/s-0028-1104604 PMID: 19221978
51. Nauck MA, Ellis GC, Fleck PR, Wilson CA, Mekki Q; Alogliptin Study 008 Group. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. Int J Clin Pract. 2009; 63(1):46-55. doi: 10.1111/j.1742-1241.2008.01933.x PMID: 19125992
52. Nauck M, Frid A, Hermansen K, Shah NS, Tankova T, Mitha IH, et al. Efficacy and safety comparison of liraglutide, glimepiride, and placebo, all in combination with metformin, in type 2 diabetes: the LEAD (liraglutide effect and action in diabetes)-2 study. Diabetes Care. 2009; 32(1):84-90. doi: 10.2337/dc08-1355 PMID: 18931095
53. Hamann A, Garcia-Puig J, Paul G, Donaldson J, Stewart M. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. Exp Clin Endocrinol Diabetes. 2008; 116(1):6-13. PMID: 18095238
54. Khanolkar MP, Morris RH, Thomas AW, Bolusani H, Roberts AW, Geen J, et al. Rosiglitazone produces a greater reduction in circulating platelet activity compared with gliclazide in patients with type 2 diabetes mellitus-an effect probably mediated by direct platelet PPARgamma activation. Atherosclerosis. 2008; 197(2):718-24. PMID: 17765245
55. Raz I, Chen Y, Wu M, Hussain S, Kaufman KD, Amatruda JM, et al. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. Curr Med Res Opin. 2008; 24 (2):537-50. doi: 10.1185/030079908X260925 PMID: 18194595
56. Scott R, Loeys T, Davies MJ, Engel SS; Sitagliptin Study 801 Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. Diabetes Obes Metab. 2008; 10(10):959-69. doi: 10.1111/j.1463-1326.2007.00839.x PMID: 18201203
57. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Care. 2007; 30(4):890-5. PMID: 17277036
58. Nauck MA, Meininger G, Sheng D, Terranella L, Stein PP; Sitagliptin Study 024 Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. Diabetes Obes Metab. 2007; 9(2):194-205. PMID: 17300595
59. Ristic S, Collober-Maugeais C, Pecher E, Cressier F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. Diabet Med. 2006; 23(7):757-62. PMID: 16842480
60. DeFronzo RA, Ratner RE, Han J, Kim DD, Fineman MS, Baron AD. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005; 28(5):1092-100. PMID: 15855572
61. Feinglos M, Dailey G, Cefalu W, Osei K, Tayek J, Canovatchel W, et al. Effect on glycemic control of the addition of 2.5 mg glipizide GITS to metformin in patients with T2DM. Diabetes Res Clin Pract. 2005; 68(2):167-75. PMID: 15860246
62. Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005; 21(2):167-74. PMID: 15386821
63. Ahrén B, Gomis R, Standl E, Mills D, Schweizer A. Twelve- and 52-week efficacy of the dipeptidyl peptidase IV inhibitor LAF237 in metformin-treated patients with type 2 diabetes. Diabetes Care. 2004; 27 (12):2874-80. PMID: 15562200
64. Gómez-Perez FJ, Fanghänel-Salmón G, Antonio Barbosa J, Montes-Villarreal J, Berry RA, Warsi G, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Diabetes Metab Res Rev. 2002; 18(2):127-34. PMID: 11994904
65. Marre M, Van Gaal L, Usadel KH, Ball M, Whatmough I, Guitard C. Nateglinide improves glycaemic control when added to metformin monotherapy: results of a randomized trial with type 2 diabetes patients. Diabetes Obes Metab. 2002; 4(3):177-86. PMID: 12047396
66. Charpentier G, Fleury F, Kabir M, Vaur L, Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet Med. 2001; 18(10):828-34. PMID: 11678974
67. Van Gaal L, Maislos M, Schernthaner G, Rybka J, Segal P. Miglitol combined with metformin improves glycaemic control in type 2 diabetes. Diabetes Obes Metab. 2001; 3(5):326-31. PMID: 11703422
68. Halimi S, Le Berre MA, Grangé V. Efficacy and safety of acarbose add-on therapy in the treatment of overweight patients with Type 2 diabetes inadequately controlled with metformin: a double-blind, placebo-controlled study. Diabetes Res Clin Pract. 2000; 50(1):49-56. PMID: 10936668
69. Fonseca V, Rosenstock J, Patwardhan R, Salzman A. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. JAMA. 2000; 283 (13):1695-702. PMID: 10755495
70. Moses R, Slobodniuk R, Boyages S, Colagiuri S, Kidson W, Carter J, et al. Effect of repaglinide addition to metformin monotherapy on glycemic control in patients with type 2 diabetes. Diabetes Care. 1999; 22(1):119-24. PMID: 10333912
71. Rosenstock J, Brown A, Fischer J, Jain A, Littlejohn T, Nadeau D, Sussman A, Taylor T, Krol A, Magner J. Efficacy and safety of acarbose in metformin-treated patients with type 2 diabetes. Diabetes Care. 1998; 21(12):2050-5. PMID: 9839093
72. Sherwood NE, Jeffery RW, French SA, Hannan PJ, Murray DM. Predictors of weight gain in the Pound of Prevention study. Int J Obes Relat Metab Disord. 2000; 24(4):395-403. PMID: 10805494
73. Unick JL, Beavers D, Jakicic JM, Kitabchi AE, Knowler WC, Wadden TA, et al. Effectiveness of lifestyle interventions for individuals with severe obesity and type 2 diabetes: results from the Look AHEAD trial. Diabetes Care. 2011; 34(10):2152-7. doi: 10.2337/dc11-0874 PMID: 21836103
74. Baker WL, Smyth LR, Riche DM, Bourret EM, Chamberlin KW, White WB. Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. J Am Soc Hypertens. 2014; 8(4):262-75. doi: 10.1016/j.jash.2014.01.007 PMID: 24602971
75. McIntosh B, Cameron C, Singh SR, Yu C, Ahuja T, Welton NJ, et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med. 2011; 5(1):e35-48. PMID: 22046219
76. Bolen S, Wilson L, Vassy J, Feldman L, Yeh J, Marinopoulos S, et al. Comparative Effectiveness and Safety of Oral Diabetes Medications for Adults With Type 2 Diabetes [Internet]. Rockville (MD): Agency for Healthcare Research and Quality (US); 2007 Jul. Available from http://www.ncbi.nlm.nih.gov/books/NBK43056/PubMed PMID: 20704051.
77. Monami M, Lamanna C, Marchionni N, Mannucci E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract. 2008; 79(2):196-203. PMID: 17931733
78. Mills EJ, Kanters S, Thorlund K, Chaimani A, Veroniki AA, Ioannidis JP. The effects of excluding treatments from network meta-analyses: survey. BMJ. 2013; 347:f5195. doi: 10.1136/bmj.f5195 PMID: 24009242